UOC
BBIO icon

UBS O'Connor’s BridgeBio Pharma BBIO Stock Holding History

UBS O'Connor’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,000
Closed -$4.38K – 512
2024
Q2 		$4.38K Buy
+35,000
New +$957K ﹤0.01% 523
2023
Q3 		– Sell
-93,900
Closed -$247K – 571
2023
Q2 		$247K Buy
93,900
+4,600
+5% +$69.2K 0.01% 473
2023
Q1 		$174K Buy
+89,300
New +$1.04M ﹤0.01% 520

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's BBIO Position: Q3 2025 in Review

UBS O'Connor sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 13,771 shares — an estimated $595K sold.

UBS O'Connor first reported a position in BBIO in Q3 2023 and held it in 7 quarters. The position peaked at $1.68M in Q4 2024. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • UBS O'Connor reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 13,771 BridgeBio Pharma shares in Q3 2025, an estimated $595K.
  • UBS O'Connor first reported a position in BridgeBio Pharma in Q3 2023 and held it in 7 quarters.
  • UBS O'Connor's BridgeBio Pharma position peaked at $1.68M in Q4 2024.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.